Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.20 USD

51.20
1,551,333

+0.77 (1.53%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $51.22 +0.02 (0.04%) 7:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Amgen Files for Repatha in the U.S., EU for Expanded Use

Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.

    Sanofi (SNY): Strong Industry, Solid Earnings Estimate Revisions

    One stock that might be an intriguing choice for investors right now is Sanofi (SNY).

      Regeneron Announces Positive Data on Carcinoma Candidate

      Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

        Big Pharma Diabetes Drugs Not So Sweet. What's in Store?

        Aales of diabetes drugs from most large pharma companies slipped in the first quarter.

          Arpita Dutt headshot

          5 Drug Stocks in Focus on World MS Day

          Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

            Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?

            We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.

              Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

              After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

                Arpita Dutt headshot

                Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

                Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

                  Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline

                  We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.

                    Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

                    Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

                      Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog

                      Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).

                        Arpita Dutt headshot

                        Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?

                        Merck (MRK) and Sanofi (SNY) are both Zacks Rank #2 (Buy) stocks. Which company looks better-positioned for the remainder of the year?

                          Arpita Dutt headshot

                          Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

                          This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

                            Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1

                            Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.

                              Kevin Cook headshot

                              Bull of the Day: Regeneron (REGN)

                              Shares launched 25% recently as Kevzara and the launch of Dupixent are expected to reignite sales growth

                                AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher

                                AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.

                                  Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

                                  Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

                                    Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

                                    Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.

                                      Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

                                      Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents

                                        BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

                                        BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.

                                          Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates

                                          Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2017 results wherein earnings missed estimates while revenues beat expectations.

                                            VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

                                            VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents

                                              Arpita Dutt headshot

                                              6 FDA Events to Watch Out for in May 2017

                                              Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.

                                                Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?

                                                Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.

                                                  Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

                                                  Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.